"Great satisfaction" for Gsk after the publication of the third Access to Medicine Index (ATM), which measures the performance of the top twenty pharmaceutical companies, with particular regard to improving access to medicines and health care in developing countries. For the third time, recalls a company release, GSK ranked first, scoring the highest score in four categories: management of access to medicine, research and development activity, ability to progress, drug donation and philanthropy.
"GSK's ranking in the ATM is a great recognition of our hard work, hard work and dedication from people across GSK, whether those working to produce the millions of doses of vaccines we ship to developing countries, those researching new treatments for diseases like malaria, dengue and tuberculosis, or our on-site staff in Africa who contribute to greater access to medicines every day. Enabling greater access to medicines is at the heart of our business. We are determined to do all that we can in terms of resources, knowledge and skills to help improve the health and well-being of people, wherever they live in the world. Our goal is to do all this while guaranteeing the sustainability of our business activities and future investment in research».
Over the past five years, added Sir Witty, this has led us to fundamentally change our business model, to ensure that our medicines and vaccines are as available and affordable as possible, to foster greater research into neglected diseases, to support communities to strengthen their health infrastructure and to form partnerships with governments, NGOs and other companies to amplify our efforts. We know we can do more – he concluded – and we will continue to challenge ourselves to adopt and deliver new ideas and new approaches to improve life around the world».
The Access to Medicine Index is an initiative of the Access to Medicine Foundation, an international non-profit association, founded in 2004 and committed to improving access to medicines. The index ranks individual pharmaceutical companies according to their efforts to improve global access to medicines into seven categories: drug donation and philanthropy, growth capacity, patents and licensing, pricing equity, research and development, public policy, general access to medicines management.
